Natus Medical Inc (NASDAQ:BABY) Institutional Investor Sentiment Analysis

Sentiment for Natus Medical Inc (NASDAQ:BABY)

Natus Medical Inc (NASDAQ:BABY) institutional sentiment increased to 1 in Q3 2018. Its up 0.11, from 0.89 in 2018Q2. The ratio has increased, as 66 institutional investors increased and started new stock positions, while 66 reduced and sold positions in Natus Medical Inc. The institutional investors in our partner’s database now hold: 28.55 million shares, down from 29.79 million shares in 2018Q2. Also, the number of institutional investors holding Natus Medical Inc in their top 10 stock positions decreased from 1 to 0 for a decrease of 1. Sold All: 13 Reduced: 53 Increased: 44 New Position: 22.

Natus Medical Incorporated provides newborn care and neurology healthcare services and products worldwide. The company has market cap of $1.15 billion. It offers services and products used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders. It currently has negative earnings. The companyÂ’s product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology; and software systems for managing and tracking disorders and diseases for public health laboratories.

The stock decreased 0.17% or $0.06 during the last trading session, reaching $34.32. About 202,697 shares traded. Natus Medical Incorporated (NASDAQ:BABY) has declined 12.80% since January 12, 2018 and is downtrending. It has underperformed by 12.80% the S&P500.

Analysts await Natus Medical Incorporated (NASDAQ:BABY) to report earnings on February, 13 before the open. They expect $0.49 earnings per share, up 16.67 % or $0.07 from last year’s $0.42 per share. BABY’s profit will be $16.38 million for 17.51 P/E if the $0.49 EPS becomes a reality. After $0.40 actual earnings per share reported by Natus Medical Incorporated for the previous quarter, Wall Street now forecasts 22.50 % EPS growth.

Rutabaga Capital Management Llc Ma holds 2.13% of its portfolio in Natus Medical Incorporated for 260,076 shares. Clean Yield Group owns 59,505 shares or 0.84% of their US portfolio. Moreover, First Wilshire Securities Management Inc has 0.7% invested in the company for 66,995 shares. The New York-based Silvercrest Asset Management Group Llc has invested 0.57% in the stock. Dafna Capital Management Llc, a California-based fund reported 37,900 shares.

Since January 1, 0001, it had 0 insider buys, and 3 selling transactions for $3.18 million activity.

More notable recent Natus Medical Incorporated (NASDAQ:BABY) news were published by: Seekingalpha.com which released: “Cowen: This 7.75% New Baby Bond Has Begun Trading On The Nasdaq With An Old Ticker Symbol – Seeking Alpha” on June 13, 2018, also Nasdaq.com with their article: “Indian drug inspectors seize J&J Baby Powder samples – Nasdaq” published on December 19, 2018, Nasdaq.com published: “Baby Boomers Are Overwhelmingly at Risk of Falling Short in Retirement – Nasdaq” on December 30, 2018. More interesting news about Natus Medical Incorporated (NASDAQ:BABY) were released by: Seekingalpha.com and their article: “Stocks gain strongly after blue Monday – Seeking Alpha” published on December 18, 2018 as well as Seekingalpha.com‘s news article titled: “A Newborn Baby Bull Market And The ‘LESADA’ Hypothesis – Seeking Alpha” with publication date: December 20, 2018.

Natus Medical Incorporated (NASDAQ:BABY) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.